ABL2 is altered in 0.19% of sarcoma patients [2].

ABL2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ACVR1B is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

APC is altered in 2.18% of sarcoma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains APC status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ASXL1 is altered in 1.67% of sarcoma patients [2].

ASXL1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATM is altered in 2.97% of sarcoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ATM status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ATR is altered in 1.49% of sarcoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BLM is altered in 1.19% of sarcoma patients [2].

BLM is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BLM status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRCA1 is altered in 1.22% of sarcoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

BRCA2 is altered in 2.73% of sarcoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDK12 is altered in 0.85% of sarcoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDK12 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN1A is altered in 0.6% of sarcoma patients [2].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN1B is altered in 1.34% of sarcoma patients [2].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CDKN2A is altered in 12.31% of sarcoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CHD4 is altered in 2.63% of sarcoma patients [2].

CHD4 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CYLD is altered in 1.05% of sarcoma patients [2].

CYLD is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DICER1 is altered in 2.61% of sarcoma patients [2].

DICER1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

DNMT3A is altered in 1.43% of sarcoma patients [2].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

ERBB2 is altered in 1.0% of sarcoma patients [2].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERBB3 is altered in 2.01% of sarcoma patients [2].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ERBB3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

EWSR1 is altered in 7.23% of sarcoma patients [2].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EZH2 is altered in 0.75% of sarcoma patients [2].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains EZH2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FGFR1 is altered in 2.21% of sarcoma patients [2].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FGFR2 is altered in 0.86% of sarcoma patients [2].

FGFR2 is an inclusion eligibility criterion in 3 clinical trials for sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 status and sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FGFR3 is altered in 1.35% of sarcoma patients [2].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for sarcoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR3 status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

FGFR4 is altered in 1.52% of sarcoma patients [2].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and sarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 1.27% of sarcoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains FLT3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

FUS is altered in 1.53% of sarcoma patients [2].

FUS is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FUS status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GATA3 is altered in 1.71% of sarcoma patients [2].

GATA3 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

HGF is altered in 0.71% of sarcoma patients [2].

HGF is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains HGF status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

IDH1 is altered in 1.32% of sarcoma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains IDH1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDM6A is altered in 1.57% of sarcoma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDM6A status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KDR is altered in 2.79% of sarcoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KDR status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KEAP1 is altered in 1.1% of sarcoma patients [2].

KEAP1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KEAP1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT is altered in 16.82% of sarcoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KIT status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2D is altered in 5.12% of sarcoma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KMT2D status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

KRAS is altered in 1.83% of sarcoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains KRAS status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAGI2 is altered in 0.14% of sarcoma patients [2].

MAGI2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MAP3K1 is altered in 1.39% of sarcoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MAP3K1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MED12 is altered in 3.07% of sarcoma patients [2].

MED12 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MET is altered in 1.39% of sarcoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MET status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MSH2 is altered in 1.26% of sarcoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MSH2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MSH6 is altered in 1.36% of sarcoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MSH6 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC is altered in 3.1% of sarcoma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MYC status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NF1 is altered in 5.89% of sarcoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NF1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NF2 is altered in 1.92% of sarcoma patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NF2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH1 is altered in 2.85% of sarcoma patients [2].

NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NOTCH2 is altered in 2.2% of sarcoma patients [2].

NOTCH2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NOTCH2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NRAS is altered in 1.38% of sarcoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NRAS status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

NSD1 is altered in 1.41% of sarcoma patients [2].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains NSD1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3C2B is altered in 2.95% of sarcoma patients [2].

PIK3C2B is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3C2B status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CA is altered in 3.04% of sarcoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CA status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3CB is altered in 0.49% of sarcoma patients [2].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3CB status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PIK3R1 is altered in 0.75% of sarcoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PTCH1 is altered in 1.82% of sarcoma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PTCH1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

PTPN11 is altered in 0.67% of sarcoma patients [2].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PTPN11 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RB1 is altered in 10.1% of sarcoma patients [2].

RB1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RICTOR is altered in 1.7% of sarcoma patients [2].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RICTOR status and sarcoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RUNX1 is altered in 0.73% of sarcoma patients [2].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SETD2 is altered in 3.05% of sarcoma patients [2].

SETD2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SETD2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SMARCA4 is altered in 2.27% of sarcoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA4 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

SOX9 is altered in 1.42% of sarcoma patients [2].

SOX9 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SOX9 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

STAG2 is altered in 1.63% of sarcoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains STAG2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TAF1 is altered in 1.09% of sarcoma patients [2].

TAF1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TAF1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TAF15 is altered in 0.24% of sarcoma patients [2].

TAF15 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TAF15 status and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TBX3 is altered in 1.01% of sarcoma patients [2].

TBX3 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TBX3 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TET2 is altered in 1.49% of sarcoma patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TET2 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53 is altered in 23.58% of sarcoma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains TP53 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].

XPO1 is altered in 0.56% of sarcoma patients [2].

XPO1 is an inclusion eligibility criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains XPO1 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [3].